Shirley Kleinman
Keine laufenden Positionen mehr
Profil
Shirley Kleinman worked as the Chief Financial Officer at Notal Vision Ltd.
She completed her undergraduate degree at Tel-Aviv University and earned an MBA from Instituto de Empresa SL.
Ehemalige bekannte Positionen von Shirley Kleinman
| Unternehmen | Position | Ende |
|---|---|---|
Notal Vision Ltd.
 Notal Vision Ltd. Medical/Nursing ServicesHealth Services Notal Vision Ltd. develops and manufactures computerized ophthalmic diagnostic devices. It develops age-related macular degeneration (AMD) monitor for patients at risk of vision loss from the devastating effects of wet AMD. The firm provides Preferential Hyperacuity Perimetry, a technology with clinical data for monitoring patients with AMD to eye care professionals. Its products are used for the detection and characterization of central and paracentral metamorphopsia in patients as an aid in monitoring progression of disease factors causing metamorphopsia, such as choroidal neovascularization. The company was founded in 2000 by Barak Azmon and Yair Alster and is headquartered in Tel Aviv, Israel. | Finanzdirektor/CFO | 24.07.2017 |
Ausbildung von Shirley Kleinman
| Tel-Aviv University | Undergraduate Degree |
| Instituto de Empresa SL | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Notal Vision Ltd.
Notal Vision Ltd. Medical/Nursing ServicesHealth Services Notal Vision Ltd. develops and manufactures computerized ophthalmic diagnostic devices. It develops age-related macular degeneration (AMD) monitor for patients at risk of vision loss from the devastating effects of wet AMD. The firm provides Preferential Hyperacuity Perimetry, a technology with clinical data for monitoring patients with AMD to eye care professionals. Its products are used for the detection and characterization of central and paracentral metamorphopsia in patients as an aid in monitoring progression of disease factors causing metamorphopsia, such as choroidal neovascularization. The company was founded in 2000 by Barak Azmon and Yair Alster and is headquartered in Tel Aviv, Israel. | Health Services |
